Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Akeli capsule vs glipizide in type 2 diabetes (Qi-Yin deficiency)
CTR20132962Phase 2Completed
- Sponsor
- Ankang Jiren Pharmaceutical
- Start
- Apr 2014
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Akeli in type 2 diabetes mellitus (T2DM), sponsored by Ankang Jiren Pharmaceutical. Started Apr 2014; status: completed.
02
Drugs
Akeli
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20132962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132962.